Related Experiment Video

Updated: Jul 18, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

Gregory J Riely1, Katerina A Politi, Vincent A Miller

  • 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 26, 2006
PubMed

Insights

Somatic mutations in the epidermal growth factor receptor (EGFR) gene predict responses to lung cancer drugs like erlotinib. Further research is needed to address remaining questions about these EGFR mutations in non-small cell lung cancer.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Somatic mutations in the epidermal growth factor receptor (EGFR) gene were identified as predictive biomarkers for erlotinib and gefitinib efficacy in non-small cell lung cancer (NSCLC) patients in 2004.
  • Since this discovery, extensive research has focused on understanding the biological mechanisms and clinical implications of these EGFR mutations.

Purpose of the Study:

  • To review the accumulated knowledge on EGFR mutations in NSCLC.
  • To identify outstanding epidemiologic, biological, and clinical questions requiring further investigation.

Main Methods:

  • Literature review and synthesis of existing research findings on EGFR mutations in NSCLC.
  • Analysis of reported biological properties and clinical relevance of these mutations.

Main Results:

  • Significant progress has been made in understanding the role of EGFR mutations in NSCLC treatment response.
  • The association between specific EGFR mutations and clinical outcomes with EGFR-targeted therapies is well-established.

Conclusions:

  • Despite substantial advancements, critical questions regarding the epidemiology, biology, and clinical management of NSCLC patients with EGFR mutations persist.
  • Further research is essential to fully elucidate these aspects and optimize treatment strategies.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...